If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 562.00
Bid: 560.00
Ask: 568.00
Change: 12.00 (2.18%)
Spread: 8.00 (1.429%)
Open: 560.00
High: 562.00
Low: 550.00
Prev. Close: 550.00
GHH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Year Trading Update

4 Apr 2023 07:00

RNS Number : 2222V
Gooch & Housego PLC
04 April 2023
 

 

For immediate release

4 April 2023

 

Gooch & Housego PLC

("G&H" or the "Company" or the "Group")

 

Half Year Trading Update

 

"Trading in line with management's expectations"

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components & systems, provides an update on trading for the six months ended 31 March 2023.

 

Trading

 

In the first half of the financial year the Group made good progress in adding additional capacity to our production facilities. Output levels have increased and we have made steady progress in reducing the level of our overdue order book.

 

Revenue for the six month period is expected to be circa £71.0 million (31 March 2022: £54.1 million) supported by favourable exchange rate movements and the effects of price increases to offset cost input inflation. As previously reported, the progress we have made with recruitment and the supply chain actions we have taken, mean we expect trading this year to be more evenly weighted between the two halves of the financial year than in prior years.

 

New orders for the Group's products from our semiconductor, data communications and next generation industrial laser markets have continued to be strong. We have secured important new programme positions with medical diagnostic customers which will replace other programmes that are now coming to the end of their life cycle. Requests for quotations for the replenishment of equipment that has been deployed into Ukraine are accelerating and we anticipate some of these will convert to new orders shortly. As previously communicated, whilst there is evidence that some of the Group's customers in certain industrial and medical laser sub markets are overstocked we expect this position to rectify itself in the second half of the financial year due to underlying end market demand.

 

As at 31 March 2023 our order book stood at £124.4 million (31 March 2022: £119.9 million), an increase of 3.8%, or a reduction of 0.1% at constant currency, compared with the same time last year. This order book provides good coverage for our expected second half revenues.

 

The Group continues to experience high input cost inflation. In order to ensure we remain competitive in the employment market we have made further upward adjustments to salary levels. We have also seen continued cost inflation from our supply chain. Our commercial team remain focused on passing on these higher costs through pricing and this will support the Group's performance in the second half of this financial year.

 

We remain in a strong financial position with a robust balance sheet and low net debt. At the half year net debt was circa £19m and the Group had $46.2m available from existing committed and uncommitted debt facilities to fund its future growth activities.

 

We expect trading for the full year to be in line with management's previously reported expectations. 

 

 

 

 

Review of the Group's strategy and interim results date

 

The review of the Group's strategy is progressing according to plan. Initial findings have been shared with the Board and we expect to provide more information when the Group's interim results for the six months ended 31 March 2023 are announced on 6 June 2023.

 

 

Charlie Peppiatt, Chief Executive Officer of Gooch & Housego, commented:

 

"I am pleased with the progress that has been made in the first half of the financial year with increasing operational output to better address the demand for our products as well as continued positive levels of customer engagement on next generation programmes and new product opportunities in all our main end markets. This is thanks to the hard work of our employees across the Group and means we are well placed to meet management's expectations for the full year.

 

 "We are on track with our review of the Group strategy and expect to be able to provide more information along with the interim results in June 2023."

 

For further information please contact:

 

Charlie Peppiatt, Chief Executive Officer

Chris Jewell, Chief Financial Officer 

Gooch & Housego PLC

+44 (0) 1460 256440

 

Mark Court / George Cleary

G&H@buchanan.uk.com

Buchanan

+44 (0) 20 7466 5000

 

Christopher Baird / David Anderson

Investec Bank plc

+44 (0) 20 7597 5970

 

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSSLFMDEDSEDL
Date   Source Headline
29th Sep 201111:52 amRNSBoard Change
8th Jun 20117:00 amRNSInterim Results
12th May 201112:24 pmRNSNotice of Results
1st Apr 20117:00 amRNSAcquisition and Trading Update
23rd Feb 20117:00 amRNSProgress Update for Today's Annual General Meeting
28th Jan 20118:10 amRNSDirector/PDMR Shareholding
25th Jan 20118:30 amRNSAcquisition of EM4
24th Jan 201112:07 pmRNSAdditional Listing
19th Jan 201111:45 amRNSUS Regulatory Approval
13th Jan 20114:55 pmRNSNotification of Interests
13th Jan 20114:55 pmRNSDirector Shareholdings
13th Jan 20114:53 pmRNSAdditional Listing
5th Jan 20111:42 pmRNSResult of EGM
16th Dec 20102:37 pmRNSProposed Acquisition, Placing and General Meeting
2nd Dec 20108:52 amRNSDividend
30th Nov 20107:00 amRNSPreliminary Results
15th Nov 20107:00 amRNSNotice of Results
5th Oct 20107:00 amRNSFull-Year Trading Update
17th Sep 20102:26 pmRNSHolding(s) in Company
13th Jul 20107:00 amRNSTrading Update
8th Jun 20107:00 amRNSInterim Results
18th May 20107:00 amRNSNotice of Results
8th Apr 20107:00 amRNSHalf-Year Trading Update
26th Mar 20103:33 pmRNSHolding(s) in Company
12th Mar 20108:56 amRNSDirector/PDMR Shareholding
25th Feb 201011:00 amRNSResult of AGM
24th Feb 20107:00 amRNSProgress Update for Today's Annual General Meeting
26th Jan 20108:24 amRNSDirector/PDMR Shareholding
18th Jan 20103:48 pmRNSAward of Share Options
7th Jan 20103:09 pmRNSAward of share-based incentives
1st Dec 20097:00 amRNSPreliminary Results
12th Nov 20098:56 amRNSNotice of Results
6th Oct 20097:00 amRNSFull-Year Trading Update
23rd Jul 20097:00 amRNSAppointment of new executive director
9th Jun 20097:00 amRNSInterim Results
13th May 20098:57 amRNSNotice of Results
2nd Apr 20097:00 amRNSResult of AGM
31st Mar 20097:00 amRNSHalf-Year Trading Update
23rd Mar 20097:00 amRNSBoard Change
9th Mar 20097:00 amRNSMarket Update
29th Jan 20094:04 pmRNSTrading Update
1st Dec 200810:56 amRNSDirector Share Dealing
25th Nov 200812:27 pmRNSPreliminary Results - Replacement
25th Nov 20087:00 amRNSPreliminary Results
5th Nov 20087:00 amRNSNotice of Results
10th Oct 20087:00 amRNSAcquisition of General Optics
9th Oct 20087:00 amRNSFull Year Trading Update
25th Sep 200811:47 amRNSInvestor and Analyst Site Visits
19th Sep 20083:11 pmRNSShare Option Purchase
4th Jul 20087:00 amRNSAcquisition of General Optics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.